Table 1 Patient characteristics and clinical ART outcome among normal weight, overweight and obese groups

Patient, n

/

84

37

17

Body mass index, kg/m^b

K

21.8^a (20.6–23.3)

26.5^b (25.7–28.4)

32.6^c (31.3–34.7)

Age, year

K

32.0 (30.0–36.8)

32.0 (29.0–35.0)

31.0 (28.0–34.5)

Total doses of urinary gonadotropins, IU

K

2252 (1819–3094)

2626 (1950–3601)

3019 (2072–4538)

Total doses of recombinant gonadotropins, IU

K

2363 (1351–3376)

1575 (1369–2104)

2288 (1425–2441)

Oocytes retrieved, n

K

14.0 (10.3–18.0)

13.0 (10.0–17.0)

13.0 (8.50–17.0)

Oocytes injected + oocytes inseminated, n

K

12.0 (9.00–15.0)

11.0 (9.00–14.0)

10.0 (7.50–14.0)

Two-pronuclei oocytes (2PN)^b, n

K

7.00 (5.00–10.0)

8.00 (6.00–9.00)

7.00 (4.50–10.0)

2PN / (oocytes injected + oocytes inseminated), %

K

71.4 (50.0–80.0)

77.4 (64.6–87.5)

66.7 (58.6–83.3)

Embryos with ≥ 6 cells on day 3, n

K

5.00 (3.00–8.00)

6.00 (5.00–8.50)

5.00 (4.00–9.00)

Embryos with ≥ 6 cells on day 3 / 2PN, %

K

80.0 (60.0–93.3)

84.6 (71.4–100)

90.0 (69.0–100)

Embryos with 8 cells on day 3, n

K

3.00 (1.00–4.00)

4.00 (2.00–5.00)

4.00 (2.00–6.00)

Embryos with 8 cells on day 3 / 2PN, %

A

37.2^a (32.2–42.3)

44.7^a (36.6–52.9)

59.5^b (48.6–70.5)

Embryo development between days 3 and 5 (ED3-5)

K

4.00 (2.00–6.00)

4.00 (2.00–6.00)

4.00 (2.50–6.50)

ED3-5 / 2PN, %

A

54.7 (48.5–60.8)

59.5 (49.5–69.5)

65.4 (53.0–77.7)

Expanded blastocysts on day 5 (EB5), n

K

1.00 (0.00–3.00)

3.00 (0.00–5.00)

2.00 (0.50–4.50)

EB5 / 2PN, %

K

20.0 (0.00–45.5)

33.3 (0.00–56.3)

30.0 (7.14–50.0)

Embryo utilization rate (EUR)^c, %

K

40.0 (22.2–53.3)

43.8 (14.3–69.0)

50.0 (31.0–70.8)

Cumulative live birth rate^d, %

Fisher's exact

50.6

45.9

47.1